As a PD-L1 immune checkpoint inhibitor, Atezolizumab has demonstrated significant efficacy in various cancers, including breast cancer, renal cell carcinoma, and bladder transitional cell carcinoma. This evidence concerns the gene CD274 and renal cell carcinoma.